AstraZeneca Pharma rises 4% on getting CDSCO nod to import cancer treatment drug

Shares of AstraZeneca Pharma India jumped over 4 percent on March 27, a day after the company informed that it has received permission to import, for sale and distribution, Trastuzumab deruxtecan lyophilized powder concentrate for solution for infusion 100mg (Enhertu) from the Central Drugs Standard Control Organisation.

Trastuzumab deruxtecan is indicated for the treatment of adult patients with unresectable or metastatic HER2-Low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy, AstraZeneca said.

It is also indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen, the pharma company informed.

Follow our market blog to catch all the live action

“The receipt of this permission paves the way for the launch of Trastuzumab deruxtecan lyophilized powder for concentrate for solution for infusion 100mg (Enhertu) in India for the specified additional indications, subject to the receipt of related statutory approvals, if any,” said AstraZeneca Pharma.

At 10:27 am, AstraZeneca Pharma shares were trading at Rs 5,204.70 on the National Stock Exchange (NSE), up 2.6 percent from the previous close. In the last one year, the stock has risen 57 percent, outperforming benchmark Nifty 50 which has risen 30 percent during the same period.

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.